FULL ARTICLE · ONLINE COLLECTION UPDATE
GLP-1 medicines and bone density: what eight trials can tell us
Some trials found lower bone density. The evidence remains too limited to establish the effects of the drug class or the risk of fractures.
Weight loss is one outcome of treatment. Bone health is another. A systematic review in Archives of Osteoporosis examined eight randomized trials involving 493 adults with overweight or obesity. Its conclusion is cautious: the available studies are too small and too different to determine the skeletal effects of GLP-1 medicines in this population.
What the review examined
The researchers searched studies published from January 2015 through July 2026. Eligible trials lasted at least 12 weeks, compared a GLP-1 medicine with placebo or another diabetes treatment, and measured bone mineral density using DXA. Five of the eight trials enrolled people with type 2 diabetes. The review reported each medicine separately rather than combining them into one class-wide estimate.
Three trials were rated at low risk of bias; five raised some concerns. No medicine had more than one low-risk trial supporting it. The certainty of evidence was very low for every agent.
Where bone-density reductions appeared
The single semaglutide trial, with 64 participants, reported lower lumbar-spine and whole-body bone density compared with placebo, alongside greater weight loss and a rise in a marker of bone breakdown. A trial of liraglutide at 3.0 mg daily also reported lower spine and hip bone density. A separate trial of liraglutide at 1.8 mg did not find material changes at the measured sites. Exenatide findings were inconsistent.
The two trials with the largest weight loss both reported bone-density reductions. That pattern deserves further investigation. It does not establish whether the changes came from weight loss, a direct drug effect, or a combination, and it cannot be transferred automatically to every GLP-1 medicine.
Bone density is not a fracture outcome
The review does not establish an increased risk of fractures. Its authors call for larger, medicine-specific trials that measure fractures. A broader 2026 review, using different eligibility criteria and analyses, reported no significant bone effects in its most-adjusted pooled analyses. These reviews should not be treated as interchangeable: their populations, study designs and synthesis methods differ.
For readers following longevity research, this is a reason to examine physical function and skeletal outcomes alongside weight and metabolic measures. It is not a reason to assume that a treatment’s benefits have disappeared, or to change an individual prescription on the basis of a headline.
Sources and review limits
Primary systematic review · PMID 42920024 · Journal DOI. Broader musculoskeletal review · PMID 42730869.
Read the earlier GLP-1 article → · Explore strength and function → · Explore sleep →